Table 2. TLR antagonists and their associated targets and diseases.
| Inhibitor | Target molecule | Disease |
|---|---|---|
| OxPAPC | CD14, MD-2, LBP | Sepsis |
| Chloroquine/hydroxychloroquine | TLR3, TLR7, TLR9 | SLE |
| Imidazoquinolines | TLR3, TLR9 | Autoimmune disease |
| Propidium iodide | TLR3, TLR7, TLR9 | Autoimmune disease |
| EM77/110 | MyD88/TIR domain interaction blockade | Inflammatory disease |
| ST2825 | Block MyD88 dimerization and interact with IRAK1 and IRAK4 | Chronic inflammatory disease |
| IMO-3100 | TLR7, TLR9 | Autoimmune disease |
| IRS-954 | TLR9 | Autoimmunity, SLE |
| E6446 | TLR9 | Inflammatory disease |
| Eritoran | TLR4 | Septic shock |
| DV1179 | TLR7, TLR9 | SLE |
| IPH-32XX | TLR7 | Autoimmune, cancer |
| E567 | TLR2, TLR4 | Anti-viral response |
Abbreviations: CD14, cluster of differentiation 14; IRAK, IL-1 receptor-associated kinase; LBP, lipopolysaccharide-binding protein; MD-2, myeloid differentiation factor 2; MyD88, myeloid differentiation 88; OxPAPC, oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine; TIR, Toll/interleukin-1 receptor; TLR, Toll-like receptors.